Copy Link Print Information

Sorafenib

(Synonyms: Bay 43-9006)
292 Cited Publications
Revisión del cliente

Based on 292 publication(s) in Google Scholar

Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.84%
  • No. CAS: 284461-73-0
  • Fòrmula: C21H16ClF3N4O3
  • Peso molecular:464.83
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Sorafenib Chemical Structure
    Sorafenib Chemical Structure
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
No. CAS: 284461-73-0
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Sorafenib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Sorafenib

More
Customer Validation & Images
Cell Imaging/StainingRT-PCRWBHistological Imaging/StainingIn Vivo Efficacy StudyCell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • Histological Imaging/Staining
  • Histological Imaging/Staining
  • Histological Imaging/Staining
  • In Vivo Efficacy Study
  • WB
  • WB
  • WB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • RT-PCR

Ver todos los productos específicos de isoformas Raf

More

Ver todos los productos específicos de isoformas VEGFR

More

Ver todos los productos específicos de isoformas STAT

More

Ver todos los productos específicos de isoformas Akt

More

Ver todos los productos específicos de isoformas MMP

More

Ver todos los productos específicos de isoformas p38 MAPK

More

Ver todos los productos específicos de isoformas ERK

More

Ver todos los productos específicos de isoformas MEK

More

Ver todos los productos específicos de isoformas PI3K

More

Ver todos los productos específicos de isoformas PARP

More

Ver todos los productos específicos de isoformas Bcl-2 Family

More
Keywords
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Sorafenib Chemical Structure
    Sorafenib Chemical Structure
    1/16
  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):87. [Abstract]

    Customer Validation
     The cell viability of YAP-, YAP-S127A-, or YAP-R124F-overexpressed Huh-7 cells cultured in methionine-deprived medium (MD) and treated with sorafenib (1.5-3 μM) for 24 h.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]

    Customer Validation
     Growth inhibition, IC50 and AUC values, of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the FLT3 inhibitors, Gilteritinib (10-1000 nM) and Sorafenib (10-1000 nM), or KIT inhibitors, Amuvanib and Telatinib

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (90-900 nM) markedly suppressed the upregulation of endothelial-like differentiation in ligament cells mediated by LOXL2.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; one daily for 14 d) significantly decreased bone volume (BV) in BMP-induced ossification mice.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) caused sparse trabecular bone structures in BMP-induced ossification mice, accompanied by numerous cartilage structures and amorphous matrix deposition, indicating a delay in endochondral ossification.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) significantly lowered the level of SP7 in BMP-induced ossification mice.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d)caused a shorter response time to thermal stimulation and less paw withdrawal threshold to mechanical stimulation of BMP-induced ossification mice.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

    Customer Validation
     Western blot to detect the ferritin H protein level by the gain or loss of URB1-AS1 in sorafenib-sensitive or sorafenib-resistant HepG2 cells.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

    Customer Validation
     qPCR showing the nuclear and cytoplasmic fractions of URB1-AS1 in sorafenib-resistant HepG2 cells with β-actin and MALAT1 as cytoplasmic and nuclear controls, respectively.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

    Customer Validation
     PANC-1 cells were transfected with the recombinant plasmid for 24 h and treated with sorafenib (0–70 μmol/L) for another 24 h, and then total cellular extracts were subjected to Western blotting using antibodies against caspase-3, GSDME and β-tubulin.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]

    Customer Validation
     HeLa and SiHa cells were treated with condition medium (CM) from human PBMC-derived M0 macrophages (Ctrl) and TAM. And then cells were treated with indicated dose of Sorafenib (Sora) for 48 h. Inhibition ratio of cell viability was detected by CCK-8 assay.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

    Customer Validation
     Sorafenib (12.5-125 μM; 24 h) inhibits the viability of PANC-1 cells in a dose-dependent manner.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

    Customer Validation
     Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

    Customer Validation
     Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]

    Customer Validation
     Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]

    Customer Validation
     SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]

    Customer Validation
     The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]

    Customer Validation
     The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]

    Customer Validation
     VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

    Customer Validation
     Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

    Customer Validation
     Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]

    Customer Validation
     Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

  • Sorafenib